ArticleTransboundary and emerging diseases2025
Safety and Efficacy Profiles of the Live Attenuated Vaccine AVAC ASF LIVE for Preventing African Swine Fever in Pigs.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Evaluation of the vaccine candidate ASFV-MEC-01: safety, efficacy, transmission dynamics, and assessment of reversion to virulence.Emerging microbes & infections · 2026Article
- African swine fever in the era of global expansion: Epidemiology, transmission dynamics, viral evolution, and One Health control strategies.Veterinary world · 2026Review
- Live-Attenuated Vaccines Against African Swine Fever: Strategies, Lessons, and Prospects.Biology · 2026Review
- Article
- Rapid Spread of Recombinant African Swine Fever Virus Genotypes I and II, Vietnam, 2023-2024.Emerging infectious diseases · 2026Article
- The Prospects and Challenges of Live Attenuated Vaccines Against African Swine Fever Virus in Vietnam.Vaccines · 2026Review
- African swine fever control in the context of endemic persistence.Frontiers in veterinary science · 2026Article
- Live Attenuated Vaccines for African Swine Fever: Perspectives on Their Use and Strategic Directions.Transboundary and emerging diseases · 2026Review
- Article
- Development of a cost-effective serodiagnosis for African swine fever using solubility-enhanced recombinant p54, p30, and p72.Veterinary world · 2025Article
- First report of acute African swine fever in pig farms on the west coast of India: pathological and molecular insights.Frontiers in cellular and infection microbiology · 2025Article
- WiBISS: a tool to estimate avoided lost revenue of African swine fever wild boar vaccination at municipality level.Frontiers in veterinary science · 2025Article
- Safe and efficient transportation of clinical samples for molecular detection of African swine fever virus.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is one of the most devastating diseases affecting the global pig industry. Therefore, the development of safe and effective vaccines is crucial in combating the virus. The AVAC ASF LIVE vaccine, produced from an attenuated genotype II ASF virus (ASFV) strain with the deletion of six MGF genes and cultured in a Diep's macrophage (DMAC) cell line, has been officially licensed for use and commercialization in Vietnam. This study evaluated the safety and efficacy of the AVAC ASF LIVE vaccine. In the safety experiment, pigs received a dose equivalent to 100 times the protective dose. In the efficacy experiment, control pigs and one-dose vaccinated pigs were challenged with a highly virulent p72 genotype II ASFV on day 28 post-vaccination. The duration of protective immunity was assessed by challenging pigs at various time points, from 2 weeks up to 6 months post-vaccination. Results showed that pigs given the 100-fold protective dose remained healthy with no abnormal signs. Significantly, 60% of vaccinated pigs survived the challenge 14 days after vaccination, and the survival rates reached 100% when challenged at 28, 90, 120, and 150 days post-vaccination (dpv). The vaccine effectively induced robust immunity, leading to a reduction in viral shedding and the persistence of viral DNA in vaccinated animals. In conclusion, the AVAC ASF LIVE vaccine has demonstrated safety and high efficacy in protecting pigs from genotype II ASFV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.